The development of improved therapies for heart disease is research-intensive and costly. This is due to complex validation and multi-stage approval procedures. These usually include extensive preclinical testing of therapeutic approaches in animal models and a multi-stage clinical trial to demonstrate safety and efficacy in patients. NumeriCor’s simulations offer enormous potential here to accelerate this development and save costs (MDDT – Software as a Medical Device Development Tool) as well as to improve therapies (SaMD – Software as Medical Device).

The business model of the start-up company from the ZWT ACCELERATOR is based on several pillars. On the one hand, it includes contract research in the field of medical technol-ogy, especially for smaller companies that want to develop new innovations. In addition, the focus is on licensing and training in simulation tools. Furthermore, support for in silico clinical trials (ISCT) plays a central role: simulation-based approval studies that can supplement and accelerate traditional clinical trials. The fourth pillar is simulation-based therapy optimization, which is currently in development and will be used directly as a clinical product in the future.